Industry/Academia Advocacy Group Presses For Stable NIH Funding
This article was originally published in The Gray Sheet
Executive Summary
United for Medical Research, a year-old advocacy organization that boasts BIO as a founding member, is bringing academic and industry groups together in a long-range effort to end the boom-or-bust funding cycles experienced by the National Institutes of Health
You may also be interested in...
Senate Subcommittee Explores Innovation Strategy, With Device Emphasis
Device, investor and technology leaders told a U.S. Senate subcommittee on June 22 that they want a more thoughtful national strategy on innovation competitiveness - one that increases collaboration between industry and university researchers and reforms often confusing regulatory roadblocks
Senate Subcommittee Explores Innovation Strategy, With Device Emphasis
Device, investor and technology leaders told a U.S. Senate subcommittee on June 22 that they want a more thoughtful national strategy on innovation competitiveness - one that increases collaboration between industry and university researchers and reforms often confusing regulatory roadblocks
People In Brief
Terumo Heart: Ann Arbor, Mich., subsidiary of the Japanese conglomerate names Thomas Gould as VP-clinical affairs and Mark Bullivant as director for international sales on Aug. 5, adding to the firms burgeoning left ventricular assist device unit. Gould comes from a VP of sales and marketing post at VentraAssist VAD developer Ventricor, which announced in March that it has run out of money. He will oversee Terumo's 140-patient U.S. pivotal trial for the DuraHeart ventricular assist device as a bridge-to-transplant (1"The Gray Sheet" April 13, 2009). Bullivant joins Terumo from St. Jude Medical's international cardiac surgery business and will focus on developing Terumo's international DuraHeart business, the company says